Eli Lilly and CompanyLLYNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +20.43% | +44.68% | +45.17% | +37.64% | +53.87% |
| Gross Profit Growth | +21.34% | +47.10% | +48.06% | +43.55% | +57.45% |
| EBITDA Growth | +133.48% | +89.42% | +33.58% | +82.35% | +250.64% |
| Operating Income Growth | +28.49% | +81.57% | +97.70% | +61.28% | +69.91% |
| Net Income Growth | +0.00% | +101.39% | +23.02% | +90.78% | +475.34% |
| EPS Growth | +0.00% | +102.06% | +23.29% | +91.49% | +475.93% |
| EPS Diluted Growth | +0.00% | +101.65% | +23.39% | +91.77% | +480.37% |
| Weighted Average Shares Growth | -5.09% | -0.20% | -0.31% | -0.33% | -0.46% |
| Weighted Average Shares Diluted Growth | -4.67% | -0.09% | -0.35% | -0.49% | -0.69% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +69.53% | +0.00% | +42.85% | +110.54% | +138.04% |
| Free Cash Flow Growth | +0.00% | +0.00% | -990.87% | +1923.66% | +0.00% |
| Receivables Growth | +16.29% | +17.11% | +39.84% | +31.55% | +61.45% |
| Inventory Growth | +52.20% | +31.46% | +52.59% | +69.93% | +63.28% |
| Asset Growth | +30.55% | +22.98% | +39.79% | +40.41% | +52.02% |
| Book Value per Share Growth | +33.72% | +32.02% | +23.43% | +35.19% | +67.85% |
| Debt Growth | +54.30% | +33.37% | +46.94% | +38.11% | +36.59% |
| R&D Expense Growth | +13.49% | +17.94% | +8.36% | +23.05% | +50.74% |
| SG&A Expenses Growth | +17.53% | +27.58% | +28.65% | +32.19% | +38.11% |